T-DXd has shown clinical activity in patients with previously treated HER2-low expression (IHC 2+/ISH-, IHC 1+) G/GEJ adenocarcinoma, without any reported new adverse effects [118]. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.